Association between CAG repeat polymorphisms and the risk of prostate cancer: A meta-analysis by race, study design and the number of (CAG)n repeat polymorphisms

Sun,Jun-Hyun; Lee,Sang-Ah

doi:10.3892/ijmm.2013.1474

Association between CAG repeat polymorphisms and the risk of prostate cancer: A meta-analysis by race, study design and the number of (CAG)n repeat polymorphisms

Authors:
- Jun-Hyun Sun
- Sang-Ah Lee
View Affiliations

Affiliations: Department of Preventive Medicine, Kangwon National University School of Medicine, Chuncheon-si, Gangwon-do 200-701, Republic of Korea
Published online on: August 23, 2013 https://doi.org/10.3892/ijmm.2013.1474
Pages: 1195-1203

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although a number of studies have been conducted on the association between prostate cancer and CAG repeat polymorphisms of the androgen receptor gene, this association remains elusive and controversial. In this meta‑analysis, we aimed to evaluate the effects of (CAG)n repeat genetic polymorphisms on the incidence of prostate cancer, particularly as regards race, study design and the number of (CAG)n repeats. To collect articles published on the association between CAG repeats and prostate cancer, publications were identified from the National Center for Biotechnology Information (NCBI) database of epidemiological studies published up to October 2011; our identification of publications was not limited by a language barrier. The following search keywords were used: prostate cancer risk, CAG repeat polymorphism, androgen receptor gene and human. Stata version 10 was used for the meta‑analysis and the publication bias was measured through the Begg's test and Egger's test. This meta-analysis included 47 studies with 13,346 cases and 15,172 control or non‑cases and consisted of 31 reports based on Caucasians, ten on Asians, one on Hispanics and four on combined ethnic groups. The carriers of a shorter CAG repeat sequence had an increased risk of prostate cancer (OR 1.21, 95% CI 1.10‑1.34 for all subjects; OR 1.21, 95% CI 1.10‑1.34 for prospective studies; OR 1.32, 95% CI 1.15‑1.51 for retrospective studies) regardless of the exact length of the CAG repeat, compared with carriers of a longer repeat sequence. In terms of race, the risk of carrying a shorter CAG repeat sequence was 1.10- and 1.83-fold higher than that of a longer repeat sequence in Caucasians and Asians, respectively. For the specific number of CAG repeat polymorphisms, carriers of <22 repeats were observed to have a higher risk of prostate cancer (OR 1.16, 95% CI 1.04‑1.29) compared with carriers with ≥22 CAG repeat polymorphisms, particularly for Asians (OR 2.06, 95% CI 1.00‑4.24). This meta‑analysis suggests that a shorter CAG repeat polymorphism may increase the risk of prostate cancer compared with the longer CAG repeat; in particular, the effect of shorter CAG repeats on the increased risk of prostate cancer was predominantly observed in Caucasians and Asians.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
2	Parkin DM, Whelan SL, Ferlay J, Raymond and Young J: Cancer incidence in five continents. VIIIARC Sci Publ; (143): pp. i–xxxiv. pp. 1–1240. Lyon: 1997
3	Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, et al: Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 58:4497–4504. 1998.PubMed/NCBI
4	Zeegers MP, Jellema A and Ostrer H: Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer. 97:1894–1903. 2003. View Article : Google Scholar : PubMed/NCBI
5	http://en.wikipedia.org/wiki/Prostate_cancer.
6	Nelson KA and Witte JS: Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol. 155:883–890. 2002. View Article : Google Scholar : PubMed/NCBI
7	Wilding G: The importance of steroid hormones in prostate cancer. Cancer Surv. 14:113–130. 1992.PubMed/NCBI
8	Crawford ED: Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology. 73(Suppl 5): S4–S10. 2009. View Article : Google Scholar : PubMed/NCBI
9	Montgomery JS, Price DK and Figg WD: The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol. 195:138–146. 2001. View Article : Google Scholar : PubMed/NCBI
10	Chamberlain NL, Driver ED and Miesfeld RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22:3181–3186. 1994. View Article : Google Scholar : PubMed/NCBI
11	Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, et al: Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet. 13:1677–1692. 2004. View Article : Google Scholar : PubMed/NCBI
12	Risio M, Venesio T, Kolomoets E, Armaroli P, Gallo F, Balsamo A, et al: Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. Cancer Epidemiol. 35:e18–e24. 2011. View Article : Google Scholar : PubMed/NCBI
13	Zeegers MP, Kiemeney LA, Nieder AM and Ostrer H: How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev. 13:1765–1771. 2004.PubMed/NCBI
14	Gu M, Dong X, Zhang X and Niu W: The CAG repeat polymorphism of androgen receptor gene and prostate cancer: a meta-analysis. Mol Biol Rep. 39:2615–2624. 2012. View Article : Google Scholar : PubMed/NCBI
15	Lindstrom S, Ma J, Altshuler D, Giovannucci E, Riboli E, Albanes D, et al: A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab. 95:E121–E127. 2010. View Article : Google Scholar
16	Ahluwalia B, Jackson MA, Jones GW, Williams AO, Rao MS and Rajguru S: Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer. 48:2267–2273. 1981. View Article : Google Scholar : PubMed/NCBI
17	Kazemi-Esfarjani P, Trifiro MA and Pinsky L: Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet. 4:523–527. 1995. View Article : Google Scholar
18	Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, et al: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA. 94:3320–3323. 1997. View Article : Google Scholar : PubMed/NCBI
19	Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S and Barrack ER: Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res. 3:1599–1608. 1997.PubMed/NCBI
20	Yoshida KI, Yano M, Chiba K, Honda M and Kitahara S: CAG repeat length in the androgen receptor gene is enhanced in patients with idiopathic azoospermia. Urology. 54:1078–1081. 1999. View Article : Google Scholar : PubMed/NCBI
21	Sawaya ME and Shalita AR: Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg. 3:9–15. 1998.PubMed/NCBI
22	Mitsumori K, Terai A, Oka H, Segawa T, Ogura K, Yoshida O and Ogawa O: Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate. 41:253–257. 1999. View Article : Google Scholar : PubMed/NCBI
23	Shibata A, Stamey TA, McNeal JE, Cheng I and Peehl DM: Genetic polymorphisms in the androgen receptor and type II 5 alpha-reductase genes in prostate enlargement. J Urol. 166:1560–1564. 2001. View Article : Google Scholar : PubMed/NCBI
24	Andersson P, Varenhorst E and Soderkvist P: Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. Eur J Cancer. 42:2833–2837. 2006. View Article : Google Scholar : PubMed/NCBI
25	Sartor O, Zheng Q and Eastham JA: Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology. 53:378–380. 1999. View Article : Google Scholar : PubMed/NCBI
26	Lange EM, Sarma AV, Ray A, Wang Y, Ho LA, Anderson SA, et al: The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study. J Hum Genet. 53:220–226. 2008. View Article : Google Scholar : PubMed/NCBI
27	Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, et al: Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 14:1262–1269. 2005. View Article : Google Scholar : PubMed/NCBI
28	Freedman ML, Pearce CL, Penney KL, Hirschhorn JN, Kolonel LN, Henderson BE and Altshuler D: Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet. 76:82–90. 2005. View Article : Google Scholar : PubMed/NCBI
29	Visvanathan K, Helzlsouer KJ, Boorman DW, Strickland PT, Hoffman SC, Comstock GW, et al: Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk. J Urol. 171:652–655. 2004. View Article : Google Scholar : PubMed/NCBI
30	Chen C, Lamharzi N, Weiss NS, Etzioni R, Dightman DA, Barnett M, et al: Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev. 11:1033–1040. 2002.PubMed/NCBI
31	Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL and Cussenot O: Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer. 92:1130–1137. 2001. View Article : Google Scholar : PubMed/NCBI
32	Platz EA, Giovannucci E, Dahl DM, Krithivas K, Hennekens CH, Brown M, et al: The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 7:379–384. 1998.PubMed/NCBI
33	Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, et al: Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. J Urol. 184:2297–2302. 2010. View Article : Google Scholar : PubMed/NCBI
34	Nicolaiew N, Cancel-Tassin G, Azzouzi AR, Grand BL, Mangin P, Cormier L, et al: Association between estrogen and androgen receptor genes and prostate cancer risk. Eur J Endocrinol. 160:101–106. 2009. View Article : Google Scholar : PubMed/NCBI
35	Silva Neto B, Koff WJ, Biolchi V, Brenner C, Biolo KD, Spritzer PM and Brum IS: Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population. Cancer Invest. 26:74–80. 2008.PubMed/NCBI
36	Das K, Cheah PY, Lim PL, Zain YB, Stephanie FC, Zhao Y, et al: Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer. Cancer Lett. 268:340–347. 2008. View Article : Google Scholar : PubMed/NCBI
37	Lindström S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, Balter KA, et al: Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate. 66:1729–1743. 2006.PubMed/NCBI
38	Okugi H, Nakazato H, Matsui H, Ohtake N, Nakata S and Suzuki K: Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. Cancer Detect Prev. 30:262–268. 2006. View Article : Google Scholar : PubMed/NCBI
39	Krishnaswamy V, Kumarasamy T, Venkatesan V, Shroff S, Jayanth VR and Paul SF: South Indian men with reduced CAG repeat length in the androgen receptor gene have an increased risk of prostate cancer. J Hum Genet. 51:254–257. 2006. View Article : Google Scholar : PubMed/NCBI
40	Sieh W, Edwards KL, Fitzpatrick AL, Srinouanprachanh SL, Farin FM, Monks SA, et al: Prostate-specific antigen and its interaction with the androgen receptor (United States). Cancer Causes Control. 17:187–197. 2006. View Article : Google Scholar : PubMed/NCBI
41	Salinas CA, Austin MA, Ostrander EO and Stanford JL: Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk. Prostate. 65:58–65. 2005. View Article : Google Scholar : PubMed/NCBI
42	Forrest MS, Edwards SM, Houlston R, Kote-Jarai Z, Key T, Allen N, et al: Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis. 8:95–102. 2005. View Article : Google Scholar : PubMed/NCBI
43	Mishra D, Thangaraj K, Mandhani A, Kumar A and Mittal R: Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population? Clin Genet. 68:55–60. 2005. View Article : Google Scholar : PubMed/NCBI
44	Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, Casey G and Witte JS: Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate. 59:69–76. 2004. View Article : Google Scholar : PubMed/NCBI
45	Gilligan T, Manola J, Sartor O, Weinrich SP, Moul JW and Kantoff PW: Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer. 3:98–103. 2004. View Article : Google Scholar : PubMed/NCBI
46	Huang SP, Chou YH, Chang WS, Wu MT, Yu CC, Wu T, et al: Androgen receptor gene polymorphism and prostate cancer in Taiwan. J Formos Med Assoc. 102:680–686. 2003.PubMed/NCBI
47	Gsur A, Preyer M, Haidinger G, Zidek T, Madersbacher S, Schatzl G, et al: Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis. 23:1647–1651. 2002. View Article : Google Scholar : PubMed/NCBI
48	Mononen N, Ikonen T, Autio V, Rokman A, Matikainen MP, Tammela TL, et al: Androgen receptor CAG polymorphism and prostate cancer risk. Hum Genet. 111:166–171. 2002. View Article : Google Scholar : PubMed/NCBI
49	Balic I, Graham ST, Troyer DA, Higgins BA, Pollock BH, Johnson-Pais TL, et al: Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol. 168:2245–2248. 2002. View Article : Google Scholar : PubMed/NCBI
50	Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA and Ferrell RE: Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res. 7:3092–3096. 2001.PubMed/NCBI
51	Xue W, Irvine RA, Yu MC, Ross RK, Coetzee GA and Ingles SA: Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res. 60:839–841. 2000.PubMed/NCBI
52	Lange EM, Chen H, Brierley K, Livermore H, Wojno KJ, Langefeld CD, et al: The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev. 9:439–442. 2000.PubMed/NCBI
53	Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, et al: Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 60:5111–5116. 2000.
54	Correa-Cerro L, Wohr G, Haussler J, Berthon P, Drelon E, Mangin P, et al: (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet. 7:357–362. 1999. View Article : Google Scholar : PubMed/NCBI
55	Edwards SM, Badzioch MD, Minter R, Hamoudi R, Collins N, Ardern-Jones A, et al: Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer. 84:458–465. 1999. View Article : Google Scholar : PubMed/NCBI
56	Ekman P, Gronberg H, Matsuyama H, Kivineva M, Bergerheim US and Li C: Links between genetic and environmental factors and prostate cancer risk. Prostate. 39:262–268. 1999. View Article : Google Scholar : PubMed/NCBI
57	Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW and Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 89:166–170. 1997. View Article : Google Scholar : PubMed/NCBI
58	Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA and Ostrander EA: Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 57:1194–1198. 1997.PubMed/NCBI
59	Li C, Gronberg H, Matsuyama H, Weber G, Nordenskjold M, Naito K, et al: Difference between Swedish and Japanese men in the association between AR CAG repeats and prostate cancer suggesting a susceptibility-modifying locus overlapping the androgen receptor gene. Int J Mol Med. 11:529–533. 2003.PubMed/NCBI
60	Kuasne H, Rodrigues IS, Fuganti PE, Losi-Guembarovski R, Ito K, Kishima MO, et al: Polymorphisms in the AR and PSA genes as markers of susceptibility and aggressiveness in prostate cancer. Cancer Invest. 28:917–924. 2010. View Article : Google Scholar : PubMed/NCBI
61	Ashtiani ZO, Hasheminasab SM, Ayati M, Goulian BS and Modarressi MH: Are GSTM1, GSTT1 and CAG repeat length of androgen receptor gene polymorphisms associated with risk of prostate cancer in Iranian patients? Pathol Oncol Res. 17:269–275. 2011. View Article : Google Scholar : PubMed/NCBI
62	Akinloye O, Gromoll J and Simoni M: Variation in CAG and GGN repeat lengths and CAG/GGN haplotype in androgen receptor gene polymorphism and prostate carcinoma in Nigerians. Br J Biomed Sci. 68:138–142. 2011.PubMed/NCBI
63	Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, et al: Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum Genet. 110:122–129. 2002. View Article : Google Scholar : PubMed/NCBI
64	Miller EA, Stanford JL, Hsu L, Noonan E and Ostrander EA: Polymorphic repeats in the androgen receptor gene in high-risk sibships. Prostate. 48:200–205. 2001. View Article : Google Scholar : PubMed/NCBI
65	Irvine RA, Yu MC, Ross RK and Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 55:1937–1940. 1995.PubMed/NCBI
66	Panz VR, Joffe BI, Spitz I, Lindenberg T, Farkas A and Haffejee M: Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men. Endocrine. 15:213–216. 2001. View Article : Google Scholar : PubMed/NCBI
67	Mittal RD, Mishra DK, Thangaraj K, Singh R and Mandhani A: Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population? Steroids. 72:335–341. 2007. View Article : Google Scholar
68	Santos ML, Sarkis AS, Nishimoto IN and Nagai MA: Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population. Cancer Detect Prev. 27:321–326. 2003. View Article : Google Scholar : PubMed/NCBI
69	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
70	Begg CB and Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 50:1088–1101. 1994. View Article : Google Scholar : PubMed/NCBI
71	Duval S and Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 56:455–463. 2000. View Article : Google Scholar : PubMed/NCBI